Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MNTA

Momenta Pharmaceuticals (MNTA) Stock Price, News & Analysis

Momenta Pharmaceuticals logo

About Momenta Pharmaceuticals Stock (NASDAQ:MNTA)

Advanced Chart

Key Stats

Today's Range
$52.48
$52.48
50-Day Range
$52.26
$52.49
52-Week Range
$12.21
$52.53
Volume
N/A
Average Volume
1.94 million shs
Market Capitalization
$6.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Momenta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MNTA Stock News Headlines

Johnson & Johnson Files for First FDA OK of Nipocalimab
Genoptix, Momenta Shares Headed for Gains
Did you spot this in the Oval Office last week?
When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to President Trump. But many viewers missed an even more important moment in that 30-second clip. One that unmistakably singled out what Futurist Eric Fry calls "possibly the best AI investment anyone could make right now." Eric believes this little-known partner to Apple could go crazy over the next 12-24 months, potentially leaving well-known AI stocks like Nvidia, Microsoft and Google in the dust.tc pixel
Eastman Kodak, Rambus: After-Hours Trading
See More Headlines

MNTA Stock Analysis - Frequently Asked Questions

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) issued its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.06. The biotechnology company earned $6.61 million during the quarter, compared to the consensus estimate of $5.84 million. Momenta Pharmaceuticals had a negative trailing twelve-month return on equity of 61.44% and a negative net margin of 757.61%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Momenta Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Exelixis (EXEL), Gilead Sciences (GILD), Novavax (NVAX), Bristol Myers Squibb (BMY) and Shopify (SHOP).

Company Calendar

Last Earnings
8/10/2020
Today
9/06/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNTA
CIK
1235010
Fax
N/A
Employees
131
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$290.05 million
Net Margins
-757.61%
Pretax Margin
N/A
Return on Equity
-61.44%
Return on Assets
-45.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.38
Quick Ratio
6.38

Sales & Book Value

Annual Sales
$23.87 million
Price / Sales
261.69
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.59 per share
Price / Book
11.43

Miscellaneous

Outstanding Shares
119,029,000
Free Float
N/A
Market Cap
$6.25 billion
Optionable
Optionable
Beta
1.71
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:MNTA) was last updated on 9/6/2025 by MarketBeat.com Staff
From Our Partners